AccessClosure announced the launch of the Mynx Cadence vascular closure device on 11 January 2011. The next generation device offers physicians smoother device deployment while maintaining all the benefits of the original Mynx.
Three design changes on the new Mynx Cadence device make it easier and more consistent to deploy. A definitive shuttle stop when deploying the sealant reduces the possibility of over-shuttling. Additionally, a single marker on the advancer tube removes any guesswork around sealant compression. Finally, a new sealant sleeve protects the sealant during deployment and shortens the procedure time by eliminating the need to pre-soak during device preparation.
“Designing enhanced solutions for vascular closure is our top priority and the design changes incorporated into the Mynx Cadence make it easier to use while maintaining the same feel our users have grown accustomed to. We believe this device provides an excellent platform for growth as we continue to expand our user base.” said Gregory D. Casciaro, president and CEO of AccessClosure
“My initial experience with the Mynx Cadence has been very positive,” said Elias Kassab, interventional cardiologist from Oakwood Hospital in Detroit, USA. “The design changes inspire increased confidence in the device, but I do not feel that I have lost any of the tactile feedback I am used to with the Mynx. These changes truly improve the experience of deploying the Mynx.”
This new device utilises a conformable, water-soluble polyethylene glycol (PEG) sealant to close the femoral artery, which dissolves within 30 days. The Mynx received its first FDA approval in May 2007, has been used in over 700,000 procedures, and is available in two sizes for 5F and 6F/7F procedural sheaths.